Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8-9

Roberto Minici¹, Michele Ammendola², Francesco Manti¹, Maria Anna Siciliano³, Marco Minici¹, Iman Komaei⁵, Giuseppe Currò⁶ and Domenico Laganà¹*

¹Radiology Unit, Department of Experimental and Clinical Medicine, Magna Graecia University, Catanzaro, Italy, ²Digestive Surgery Unit, Science of Health Department, Magna Graecia University, Catanzaro, Italy, ³Medical Oncology Unit, Department of Experimental and Clinical Medicine, Magna Graecia University, Catanzaro, Italy, ⁴National Research Council (Cnr), Institute for High Performance Computing and Networking (ICAR), Rende, Italy, ⁵Department of Human Pathology of Adult and Evolutive Age, University of Messina, Messina, Italy, ⁶General Surgery Unit, Science of Health Department, Magna Graecia University, Catanzaro, Italy

According to the EASL Guidelines for the management of hepatocellular carcinoma, transcatheter arterial chemoembolization is the first-line treatment recommended for intermediate-stage HCC. Furthermore, it is widely accepted that patients beyond the Milan criteria can be considered for a liver transplant after successful downstaging to within the Milan criteria. Response to downstaging treatments significantly influences not just drop-outs, but also the rate of post-transplantation tumor recurrences. TACE with degradable starch microspheres represents an alternative to conventional TACE with lipiodol and TACE with drug-eluting beads, and it leads to transient arterial occlusion allowing lower activation of hypoxia-inducible factors and less release of vascular endothelial growth factor, a promoter of neoangiogenesis, tumor proliferation, and metastatic growth. In patients with intermediate-stage HCC and a Child-Pugh score of 8 or 9, life expectancy may be dominated by cirrhotic liver dysfunction, rather than by the tumor progression itself; hence, locoregional treatments might also be detrimental, precipitating liver dysfunction to an extent that survival is shortened rather than prolonged. Data on tolerability, toxicity, and effectiveness of DSM-TACE are limited but encouraging. Between January 2015 and October 2020, 50 consecutive patients with...
INTRODUCTION

Liver cancer has the seventh highest number of new cases and is the third leading cause of cancer-related death worldwide, with 841,080 new cases and 781,631 deaths per year (Bray et al., 2018). According to the EASL Guideline for the management of hepatocellular carcinoma (Galle et al., 2018), TACE is the first-line therapy recommended for intermediate-stage hepatocellular carcinoma or stage B disease, classified according to the Barcelona-Clinic Liver Cancer staging system (Llovet et al., 1999; Forner et al., 2010). The efficacy of TACE has been investigated in a few randomized trials compared with best supportive care and in a cumulative meta-analysis (Llovet and Bruix, 2003). The benefit of TACE in improving overall survival was demonstrated for patients in the Child-Pugh A stage, with early or intermediate BCLC disease, who had a small tumor burden but were unfit for surgery and for ablative therapies. In this population, it is possible to assume a median OS of 30–45 months (Golferi et al., 2014; Burrel and Reig, 2012). A median OS inferior to 20 months has been reported in real-life cohorts when patients with no proven benefit are treated including those in the Child-Pugh B stage or those with deteriorating liver function under TACE (Kirstein et al., 2017). According to the EASL Guideline for the management of hepatocellular carcinoma (Galle et al., 2018), patients with intermediate-stage HCC and Child-Pugh A-B liver function may have a dismal outcome without transplantation if refractory ascites and events such as spontaneous bacterial peritonitis, hyponatremia, or recurrent encephalopathy occur. In such a cohort, a liver transplant is reckless and if HCC surpasses the agreed criteria, the patient must be classified as BCLC-D. Interventional studies usually exclude this population subset because of its high short-term mortality. Hence, a broad variety of patients are included in the intermediate-stage HCC definition, triggering controversies to further stratify the BCLC-B category (Bolondi et al., 2012). Furthermore, it is widely accepted that patients outside the Milan criteria can be considered for liver transplant after successful downstaging to within the Milan criteria, within specified protocols (Galle et al., 2018). Response to downstage therapies has a major effect not just on drop-outs, but also on the rate of post-transplantation tumor recurrences (Cucchetti et al., 2011; Yao et al., 2015). Interestingly, the efficacy of downstage therapies is correlated with the presence of histological markers of good prognosis in the treated HCC, (i.e. the absence of microvascular invasion and satellites, low-grade tumor), similar to patients receiving LT within the Milan criteria at presentation. Thus, the response to downstaging has an important role in predicting tumor aggressiveness (Mazzaferro et al., 2011; Yao et al., 2015). Among locoregional therapies to downstage HCC, TACE is widely used and investigated in clinical practice (Parikh et al., 2015; Bryce and Tschochatzis, 2017; Affonso et al., 2019) and in small case-series regarding TACE with degradable starch microspheres (Orlacchio et al., 2015). DSM-TACE represents an option with respect to conventional TACE with lipiodol or TACE with drug-eluting beads (DEB-TACE) (Gross and Albrecht, 2020). Starch microspheres lead to transient arterial occlusion of a maximum of 50 min in vivo before they are degraded by serum alpha-amylase (Aronsen et al., 1979), achieving an increase in the intratumoral concentration of the cytostatic agent (Ebert et al., 2013). Temporary occlusion decreases the stimulation of hypoxia-inducible factors and the release of vascular endothelial growth factor, a promoter of neoangiogenesis, tumor proliferation, and metastatic growth (Li et al., 2004), making DSM-TACE a powerful tool among therapeutic strategies to control cancer, targeting the tumor stromal environment in combination with classic chemotherapeutic agents. However, there is a paucity of data on the tolerability, toxicity, and effectiveness of DSM-TACE (Niessen et al., 2014), and further clinical investigations should be encouraged. In patients with intermediate-stage HCC and a Child-Pugh score of 8 or 9, life expectancy may be determined by cirrhotic liver dysfunction, so the achievement of a balance between the safety and efficacy profile of the TACE treatment is crucial.

Keywords: hepatocellular carcinoma, downstaging, transcatheter arterial chemoembolization, degradable starch microsphere, transarterial, doxorubicin, stromal microenvironment, tumor angiogenesis
curative intent. On the other side, locoregional treatments might also be detrimental, precipitating liver dysfunction to the extent that survival is shortened rather than prolonged. Technically, there could be certain patients in this population subset, without jaundice and with only moderate ascites, who may be candidates for super-selective DSM-TACE, a tool that can face the challenge of downstaging disease within the Milan criteria, keeping an acceptable safety profile. These patients, if transplanted, may achieve good survival, which exceeds 50% at five years (Mazzaferro et al., 2009). Considering what was previously written, this study aims to evaluate the safety and efficacy of DSM-TACE in the downstaging of intermediate-stage hepatocellular carcinoma in patients with a Child-Pugh score of 8 or 9.

**MATERIALS AND METHODS**

**Study Design**

Institutional Review Board approval and informed written consent from each patient was obtained. This study is a single-center, retrospective analysis of prospectively collected data of consecutive patients with intermediate-stage hepatocellular carcinoma and a Child-Pugh score of 8/9, who had undergone, from January 2015 to October 2020, DSM-TACE as the first-line treatment.

Inclusion criteria were: I) intermediate-stage (B)—according to the Barcelona-Clinic Liver Cancer staging system (Llovet et al., 1999; Forner et al., 2010)—hepatocellular carcinoma, diagnosed with histological assessment or non-invasive imaging-based criteria used by the European Association for the Study of the Liver (Galle et al., 2018); II) Child-Pugh stage B with a score of 8 or 9; III) age between 18 and 75 years; IV) no previous treatment for HCC; V) Eastern Cooperative Oncology Group performance status (Oken et al., 1982) grade 0; and VI) evaluation by a multidisciplinary team of a hepatologist, oncologist, liver surgeon, and interventional radiologist. The exclusion criteria were: I) missed radiological evaluations at follow-up; II) serum creatinine levels >2.0 mg/dl; III) platelet count <50000/μL and/or international normalized ratio >1.5; IV) serum bilirubin level ≥3 mg/dl; and V) doxorubicin administration contraindications.

**Intervention**

At baseline condition, at least three weeks before the first treatment, all patients underwent a clinical, biochemical, and imaging examination. Imaging evaluation was performed with contrast-enhanced computed tomography and/or gadolinium-enhanced magnetic resonance imaging, using a multiphase liver imaging protocol.

DSM-TACE was performed according to the evaluation made by a multidisciplinary team. DSM-TACE was carried out in a dedicated angiography suite, monitoring vital signs during anesthesia, by the same experienced interventional radiologists (30 and 2 years of experience, respectively). All patients were pre-medicated with a proton-pump inhibitor (omeprazole 40 mg i.v.), a prokinetic drug (metoclopramide 10 mg i.v.), and an analgesic drug (ketorolac-tromethamine 20 mg i.v.); if requested, conscious sedation was performed during the procedure. The treatment was performed through a femoral or radial approach, with a Seldinger needle, by using a 5-Fr arterial introducer sheath (Terumo, Tokyo, Japan). The selective celiac trunk catheterization and the cannulation of the common hepatic artery were performed with a 5-Fr diagnostic catheter (Cobra, Simmons; Terumo). The appropriate anatomy of the hepatic artery and any possible branches related to non-target structures and any possible arteriovenous fistulae were identified through a hepatic artery angiography. After diagnostic angiography, a selective lobar catheterization was performed with a coaxial technique, placing a 2.7-Fr microcatheter (Progreat; Terumo) in the right or left hepatic artery that was feeding the involved lobe. A selective lobar angiography was then performed to confirm the correct position of the microcatheter, to identify non-hepatic arteries, and limit any possible extrahepatic diffusion of the microspheres. In particular, the identification of the cystic artery was recommended to ensure that the catheter tip would bypass this anatomical point to avoid non-target embolization. A super-selective (segmental or sub-segmental) approach was obtained using the aforementioned microcatheter. DSMs were mixed with non-ionic iotted contrast medium: 6 ml of nonionic iotted contrast was used per 4 ml of DSMs before injection. Doxorubicin at a dose of 50 mg was diluted in 5 ml of normal saline. No dose adjustment was made for bilirubin concentration or body surface area. An appropriate suspension of DSMs, contrast medium, and doxorubicin was obtained before delivery. The mixture in the syringes was constantly shaken to avoid sedimentation and disaggregation of the microspheres, then slowly injected under fluoroscopic guidance at the proper site, until stasis was observed. Stasis was defined as the absence of antegrade flow within a vessel such that contrast filling of the target vessel persisted, without washout, five cardiac beats after the injection of contrast (Brown et al., 2016). When stasis had been reached, a mixture of starch microspheres (4 ml) with contrast medium (6 ml) was slowly injected until a complete embolization was obtained.

All patients underwent physical examination, laboratory tests, and imaging follow-up at one month after each treatment and every three months thereafter if no additional treatment was required. For each patient, the imaging modality (an abdominal contrast-enhanced CT or MRI examination) remained the same throughout the entire study period.

DSM-TACE treatments were repeated on-demand upon the demonstration of a viable tumor (absence of CR) in patients who continued to meet the inclusion criteria until one of the following endpoints has been reached: 1) CR or response able to achieve successful downstaging within the Milan criteria; 2) technical impossibility to embolize the residual tumor, for example, in a tumor only supplied by extrahepatic collateral arteries; 3) development of contraindications to DSM-TACE; 4) PD after each of two consecutive DSM-TACE treatments; and 5) worsening of liver function up to Child-Pugh stage C.

**Outcomes**

The primary efficacy endpoint was the time-to-event analysis (time-to-downstaging), which examined the efficacy of
DSM-TACE as a downstaging therapy in a patient with stage B HCC and a Child-Pugh score of 8/9. Patients’ data were censored at the end of the follow-up (October 31, 2020), at the time of study withdrawal, at the time HCC stage progressed, or if death had occurred. The secondary efficacy endpoints included the radiological response to treatment, the overall survival, the progression-free survival, and the proportion of patients successfully downstaged. The overall survival was calculated as the time from the study inclusion date until death or the last follow-up. The progression-free survival was measured from the study inclusion date to disease progression.

The primary safety endpoint was the incidence of serious adverse events, in accordance with the classification set out in the next paragraph. The secondary safety endpoints were the incidence and severity of adverse events, including liver function parameters and laboratory abnormalities.

Definitions

Technical success was defined as the ability to deliver the full planned dose of doxorubicin and to obtain stop flow (Basile et al., 2012). Treatment response was assessed using mRECIST guidelines (Lencioni and Llovet, 2010). Complete response was defined as the disappearance of any intratumoral arterial enhancement in all target lesions. Partial response was defined as at least a 30% decrease in the sum of the diameters of viable (contrast-enhancing) target lesions. Progressive disease was defined as an increase of at least 20% in the sum of the diameters of the viable (enhancing) target lesions, and stable disease included all cases that did not qualify as either partial response or progressive disease. Patients developing new lesions, vascular invasion, and/or metastases were categorized as having PD. As previously reported (Lammer et al., 2010; Zhang et al., 2018), disease control was defined and calculated as CR + PR + SD. Responders referred to objective response, namely the sum of patients who experienced CR or PR. Non-responders referred to the sum of patients who had stable disease or progressive disease.

The initial response was defined as the radiological response after the first DSM-TACE. The best response was defined as the best radiological response across repeated DSM-TACE sessions. Patients who achieved an objective response after the first treatment or after the following ones were considered as initial or best responders, respectively. Sustained response duration was defined as the time between the date when CR, PR, or stable disease was achieved and the date progressive disease occurred.

All adverse events were graded using the National Cancer Institute Common Terminology Criteria for adverse events, version 4.0 (National Institute of Cancer, 2010), except for clinical complications associated with chemoembolization recorded using the CIRSE Classification System for Complications (Filippiadis et al., 2017). In reference to the CTCAE, toxicity was further graded using binary variables (mild: grades 1–2; serious: grades 3–4), adapted, and modified from (Kang et al., 2020).

Statistical Analysis

Data were maintained in an Excel spreadsheet (Microsoft Inc., Redmond, Wash), and the statistical analyses were performed using SPSS software (SPSS, version 22 for Windows; SPSS Inc., Chicago IL, United States) and R/R Studio software. The analysis of efficacy was based on the Modified Intention-To-Treat population, defined as all randomized patients who received at least one chemoembolization; this also defined the safety population. The Kolmogorov-Smirnov test and Shapiro-Wilk test were used to verify the normality assumption of data. Categorical data are presented as frequency (percentage value). Continuous normally distributed data are presented as mean ± standard deviation. Continuous not normally distributed data are presented as median (interquartile range: 25th and 75th percentiles—IQR). The unpaired Student t-test was used to assess statistical differences for continuous normally distributed data, while categorical and continuous not normally distributed data were assessed using the Chi-squared test and the Mann-Whitney test, respectively. Kaplan-Meier survival analysis was performed to assess time-dependent outcomes, and comparisons were made with the log-rank test.

The independence between censored data and the tested events was assessed by clinical evaluation and telephone contacts in the cases of withdrawal. Hence, the assumption of independent censoring was met, avoiding bias regarding the observed time-dependent data. Among all survivors (with and without drop-out from the transplant list), follow-up ended on October 31, 2020. Univariate and multivariate analyses, using Cox proportional hazards and logistic regression models, were performed to identify individual predictors (patient/lesion characteristics) associated with successful downstaging while controlling for all other predictors in the model. A p-value of <0.05 was considered statistically significant for the aforementioned tests.

RESULTS

Patient and Pathology Data

Between January 2015 and October 2020, 50 consecutive patients with intermediate-stage hepatocellular carcinoma and a Child-Pugh score of 8/9, who had undergone DSM-TACE as the first-line treatment, were eligible for the study. All patients received at least one chemoembolization treatment, meeting the criteria to be included in the Modified Intention-To-Treat (MITT) population. No patients were lost to follow-up. The mean age was 44.1 years and 80% of the patients were male. Among liver comorbidities, 12% of the patients had the hepatitis B virus, 40% the hepatitis C virus, 8% non-alcoholic fatty liver disease, and 44% alcoholic liver disease. The median alpha-fetoprotein and carbohydrate antigen 19–9 levels at the time of listing were 447 ng/ml and 11.3 U/ml, respectively. All patients were affected by cirrhosis; Child-Pugh score was B8 (84%) or B9 (16%). A total of 24% of the patients had encephalopathy, while none had ascites. The median values of neutrophil-to-lymphocyte ratio and lymphocyte-to-monocyte ratio were 3.8 and 8.4, respectively. In total, 36% of the patients had one tumor nodule, 32% of the patients had two tumor nodules, and the other 32% had three tumor nodules; the median maximum tumor size was 4.1 cm (3.3–5.1 cm). A total of 22 patients (44%) had bilobar disease, while 28 patients (56%) had capsulated tumors.
Demographics and tumor data of the study population are reported in Table 1.

### Procedure Data
A total of 142 DSM-TACEs were performed, with a mean number of 2.84 procedures per patient. The chemoembolization pattern was selective in 133 procedures (93.7%) and lobar in nine (6.3%); no procedure was performed with the catheter placed in the common hepatic artery.

Procedure data are reported in Table 2.

### Efficacy Outcomes
Technical success was achieved in 142 procedures (100%). The average follow-up was 20.8 months. After the first DSM-TACE, CR was achieved in four out of 50 patients (8%), PR in 12 (24%), SD in 26 (52%), and PD in eight (16%), with 34 (68%) non-responders, 16 (32%) responders, and disease control achieved after 42 (84%) procedures. A second DSM-TACE was performed in 38 cases, after which CR was achieved in two patients (5.3%), PR in six (15.8%), SD in 16 (42.1%), and PD in 14 (36.8%), with 30 (78.9%) non-responders, 8 (21%) responders, and disease control achieved after 24 (63.1%) procedures. A third DSM-TACE was performed in 34 cases, after which no CR was achieved, PR was achieved in 14 patients (41.2%), SD in 10 (29.4%), and PD in 10 (29.4%), with 20 (58.8%) non-responders, 14 (41.2%) responders, and disease control achieved after 24 (70.6%) procedures. A fourth DSM-TACE was performed in 20 cases, after which no CR and PR were achieved, SD was achieved in six patients (30%) and PD in 14 (70%), with 20 (100%) non-responders, 0 (0%) responders, and disease control achieved after six (30%) procedures. Considering the best response across repeated DSM-TACE sessions for each patient, CR was achieved in six out of 54 patients (12%), PR in 28 (56%), SD in 12 (24%), and PD in four (8%), with 16 (32%) non-responders, 34 (68%) responders, and disease control achieved in 46 patients (92%). Twenty-six (52%) patients achieved a sustained response duration (SRD) of six months or more; the rest of the patients (48%) achieved an SRD of less than six months. The mean time-to-downstaging was 19.2 (±9.3) months, with six patients (12%) successfully downstaged. The cumulative rates of patients successfully downstaged were about 8% (±0.04) at six months, 12% (±0.05) at 12 months, and 12% (±0.05) at 24 months. Death occurred in 28 cases (56%) along the follow-up period. OS was about 100% (±0.00) at six months, 81.8% (±0.06) at 12 months, and 50% (±0.07) at 24 months. For patients with SRD of more than six months, the median (CI) OS was 35 (35-NA) months, better than that of patients with SRD of less than six months (median OS, 16.5 [15–23] months) (p = 0.0003, calculated by mean of Log-Rank test). Progression-free survival was about 66% (±0.07) at six months, 37% (±0.08) at 12 months, and 16% (±0.06) at 24 months with only two residual patients at risk.

The efficacy outcomes are shown in Table 2, Table 3, Figure 1, and Figure 2.

Details of the predictors of successful downstaging are listed in Table 4. Based upon the intention to treat on both univariate and multivariate analyses, number of tumor nodules equal to one (HR, 1.4; 95% CI, 1.0–1.7; P 0.02), presence of tumor capsule (HR, 1.4; 95% CI, 1.0–1.7; P 0.02), objective response as the best response across repeated DSM-TACE sessions for each patient (HR, 1.5; 95% CI, 1.1–2.0; P 0.01), objective response as the initial response (HR, 1.5; 95% CI, 1.2–2.0; P 0.01), SRD of six months or more (HR, 1.6; 95% CI, 1.2–2.2; p < 0.01), and lymphocyte-to-monocyte ratio ≥ 4/neutrophil-to-lymphocyte ratio < 7.2 (HR, 1.7; 95% CI, 1.5–2.4; p < 0.01) were found to be the independent prognostic factors for successful downstaging.

### Safety Outcomes
According to the CIRSE Classification System for Complications, 16 patients (32%) experienced postprocedural clinical complications associated with chemoembolization. Apart from two treatment-related grade 3 events (non-surgical cholecystitis), only grade 1 events occurred (14 cases, 28%). These were pain responses to analgesics (10 DSM-TACEs, 20%), post-embolization syndrome (2 DSM-TACEs, 4%), transient nausea (1 DSM-TACEs, 2%), and vomiting (1 DSM-TACEs, 2%). The aforementioned adverse events were transient and easily solved with standard analgesic or antiemetic medication during interventions.

According to the CTCAE classification, 22 patients (44%) experienced adverse events after chemoembolization. Grade 1 events were observed in 12 out of 54 patients (24%), grade 2 events in eight (16%), and grade 3 events in two (4%); no grade 4
## TABLE 2 | Procedure and outcomes data.

| Variables | All patients (n=50) |
|-----------|---------------------|
| Total number of DSM-TACEs | 142 |
| Mean number of DSM-TACEs per patient | 2.84 |
| Mean follow-up (months) | 20.8 |
| Technical success, no/yes | 0 (0%) / 142 (100%) |
| Chemoembolization pattern | |
| Selective/Superselective | 133 (93.7%) |
| Lobar | 9 (6.3%) |
| Global | 0 |
| Tumour response to first DSM-TACE (No.) | |
| CR | 4 (8%) |
| PR | 12 (24%) |
| SD | 26 (52%) |
| PD | 8 (16%) |
| Non-responders (SD+PD) | 34 (68%) |
| Responders or OR (CR+PR) | 16 (32%) |
| DC (CR+PR+SD) | 42 (84%) |
| Tumour response to second DSM-TACE (No.) | |
| CR | 2 (5.3%) |
| PR | 6 (15.8%) |
| SD | 16 (42.1%) |
| PD | 14 (36.8%) |
| Non-responders (SD+PD) | 30 (78.9%) |
| Responders or OR (CR+PR) | 8 (21%) |
| DC (CR+PR+SD) | 24 (63.1%) |
| Tumour response to third DSM-TACE (No.) | |
| CR | 0 (0%) |
| PR | 14 (41.2%) |
| SD | 10 (29.4%) |
| PD | 10 (29.4%) |
| Non-responders (SD+PD) | 20 (58.8%) |
| Responders or OR (CR+PR) | 14 (41.2%) |
| DC (CR+PR+SD) | 24 (70.6%) |
| Tumour response to fourth DSM-TACE (No.) | |
| CR | 0 (0%) |
| PR | 0 (0%) |
| SD | 6 (30%) |
| PD | 14 (70%) |
| Non-responders (SD+PD) | 20 (100%) |
| Responders or OR (CR+PR) | 0 (0%) |
| DC (CR+PR+SD) | 6 (30%) |
| Best Response (No.) | |
| CR | 6 (12%) |
| PR | 28 (56%) |
| SD | 12 (24%) |
| PD | 4 (8%) |
| Non-responders (SD+PD) | 16 (32%) |
| Responders or OR (CR+PR) | 34 (68%) |
| DC (CR+PR+SD) | 46 (92%) |
| Sustained Response Duration (SRD), <6 months/≥6 months | 24 (48%) / 26 (52%) |
| Time-to-downstaging (months) | 19.2 (±9.3) |
| Event, censoring/death | 22 (44%) / 28 (56%) |
| Event, censoring/downstaging | 44 (88%) / 6 (12%) |
| Post-procedural clinical complications (CIRSE class.), absent/present | 34 (68%) / 16 (32%) |
| Grade 1 | 14 (28%) |
| Grade 2 | 0 (0%) |
| Grade 3 | 2 (4%) |
| Adverse Events (CTCAE), absent/present | 28 (56%) / 22 (44%) |
| Grade 1 | 12 (24%) |
| Grade 2 | 8 (16%) |
| Grade 3 | 2 (4%) |
| Grade 4 | 0 (0%) |
| Serious Adverse Events | 2 (4%) |
adverse events were observed. Hence, only two (4%) serious adverse events occurred, namely, grade 3 or 4 adverse events according to the Common Terminology Criteria for adverse events.

Details are given in Table 2.

**DISCUSSION**

Current guidelines consider TACE the standard of care for patients with intermediate-stage HCC who are not LT candidates, according to the BCLC staging system (EASL guidelines, 2018; ESMO guidelines, 2018) (Galle et al., 2018; Vogel et al., 2018). Since two randomized controlled trials demonstrated an improvement of OS with TACE compared to best supportive care, it has been a mainstay of treatment for unresectable HCCs (Llovet et al., 2002; Lo et al., 2002), identifying treatment response as an independent predictor of survival (Llovet and Bruix, 2003). However, it is not a risk-free method and so to reduce the systemic concentration of the cytotoxic drug, maximizing instead the intratumoral one, and to obtain a calibrated ischemia of the tumor vessel, alternative procedures have been studied such as DEB-TACE and DSM-TACE (Varela et al., 2007; Gross and Albrecht, 2020). Most of the transarterial approaches may be repeated several times when an incomplete response is achieved or in the case of tumor recurrence with an excellent safety profile, in a high volume center (Sieg hart et al., 2013). Moreover, intermediate-stage HCC (B-BCLC) represents a highly heterogeneous scenario which would require more reasoned sub-classification (Bolondi et al., 2012). Indeed, this population includes patients with multinodular, not severely compromised liver function (Child-Pugh A and B) and ECOG PS 0; it is clear that within this definition there can be patients with very different clinical, morphological, and prognostic features. Particularly, as per current guidelines, patients with bulky disease, multinodular spread, or compromised liver function may not be optimal TACE candidates and other LRT should be evaluated (Galle et al., 2018).

In patients with intermediate-stage HCC and a Child-Pugh score of 8 or 9, life expectation is negatively influenced by cirrhotic liver dysfunction, rather than by the tumor growth itself (Bolondi et al., 2012). Furthermore, it is widely accepted that patients outside the Milan criteria can be considered for liver transplant after successful downstaging to within the Milan criteria, within specified protocols (Galle et al., 2018). Response to downstage therapies has a major effect on the rate of drop-outs, on the rate of post-transplantation tumor recurrences (Cucchetti et al., 2011; Yao et al., 2015), and is linked to the presence of good prognosis histology, (i.e. the absence of microvascular invasion and satellites, low-grade tumor), similar to patients that met the Milan criteria already at the diagnosis. Therefore, the

| Cumulative Rates | At 6 months | At 12 months | At 24 months |
|------------------|-------------|-------------|-------------|
| Patients successfully downstaged | 8% (±0.04) | 12% (±0.05) | 12% (±0.05) |
| Progression-free Survival (PFS) | 66% (±0.07) | 37% (±0.08) | 16% (±0.08) |
| OS according to SRD < 6 m | 100% (±0.00) | 80% (±0.08) | 20% (±0.08) |
| OS according to SRD > 6 m | 100% (±0.00) | 85% (±0.08) | 75% (±0.09) |

**FIGURE 1** Cumulative incidence of patients successfully downstaged.
downstage response plays an important role in the prediction of tumor aggressiveness (Mazzaferro et al., 2011; Yao et al., 2015). Additionally, down-staged tumors, initially exceeding the Milan Criteria, can achieve post-transplant five-year survival and HCC recurrence-free probability just like patients that ab-initio met the Milan criteria (Yao et al., 2015). To give further insight into this unmet medical need, this study aimed to evaluate the safety and efficacy of DSM-TACE in the downstaging of intermediate-stage HCC in patients with a Child-Pugh score of 8 or 9.

With regard to tumor burden, in our analysis, the percentage of patients with one, two, or three tumors were homogeneous, with a maximum tumor size of 5.1 cm at the third quartile and bilobar disease in 44% of patients. In other prospective trials, tumors were smaller with a median tumor size of 2.6 cm and 20.9% had bilobar disease (Goliferi et al., 2014), while in the study of Gross et al. tumor burden was slightly higher. The mean time-to-downstaging, the primary endpoint of this study, was 19.2 (±9.3) months, with 12% of patients successfully downstaged. The cumulative rates of patients successfully downstaged were about 8% (±0.04) at six months, 12% (±0.05) at 12 months, and 12% (±0.05) at 24 months. OS was about 100% at six months, 81.8% at 12 months, and 50% at 24 months. To the best of our knowledge, this is the first study exploring the role of SRD as a prognostic factor after DSM-TACE. For patients with SRD of more than six months, the median OS was 35 months, better than that of patients with SRD of less than six months (median OS, 16.5 months). Based upon the intention to treat on both univariate and multivariate analyses, the number of tumor nodules equal to one, presence of tumor capsule, objective response as the best response across repeated DSM-TACE sessions for each patient, objective response as the initial response, SRD of six months or more, and lymphocyte-to-monocyte ratio ≥4/neutrophil-to-lymphocyte ratio <7.2 were found to be the independent prognostic factors for successful

FIGURE 2 | (A–B) Time-to-event analysis (listing to progression) (A) and time-to-event analysis (listing to death), according to sustained response duration (SRD) (B).
downstaging. Zhang et al. reported similar data using downstaging cTACE concluding that tumor burden (tumor number, tumor size) and tumor structure (tumor capsule) have a pivotal role in determining overall success rates of procedures (Zhang et al., 2018). Our analysis also shows the role of achieving an objective response after the first treatment, an SRD of six months or more and other parameters such as LMR–NLT of six months or more and other parameters such as LMR and NLT have a pivotal role in determining overall success rates of procedures (Lammer et al., 2010; Brown et al., 2016; Lencioni et al., 2016; Gruber-Rouh et al., 2018).

Limitations of this study include the fact that the research was based on a retrospective, single-center, and non-randomized design, the small study population and the lack of literature data in this field needed to evaluate the congruence and the consistency of the data presented. Thus, randomized-controlled clinical trials should be performed to validate our results in the downstaging of intermediate-stage hepatocellular carcinoma in patients with a Child-Pugh score of 8-9.

**CONCLUSION**

To the best of our knowledge, no observational studies have so far investigated the efficacy and safety profile of DSM-TACE in the downstaging of intermediate-stage hepatocellular carcinoma in patients with a Child-Pugh score of 8-9.

Hence, the results of the current investigation demonstrate that DSM-TACE is effective and safe in intermediate-stage HCC, achieving an interesting downstaging rate. Such data were observed in the population subset with a Child-Pugh score of 8 or 9, in which life expectancy may be dominated by cirrhotic liver dysfunction, rather than by the tumor progression itself, so that the achievement of a balance between the safety and efficacy profile of TACE treatment is crucial.

Larger, randomized controlled trials are necessary to confirm these preliminary data.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
REFERENCES

Affonso, B. B., Galastri, F. L., da Motta LealFilho, J. M., Nasser, F., Falsarella, P. M., Cavalcante, R. N., et al. (2019). Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging. World J. Gastroenterol. 25 (37), 5687–5701. doi:10.3748/wjg.v25.i37.5687

Aronsen, K. F., Hellkant, C., Holmberg, J., Rothman, U., and Teder, H. (1979). Controlled blocking of hepatic artery flow with enzymatically degradable microspheres combined with oncolytic drugflow with enzymatically degradable microspheres combined with oncolytic drugs. Eur. Surg. Res. 11 (2), 99–106. doi:10.1159/000128056

Basile, A., Carrafiello, G., Ierardi, A. M., Tsetis, D., and Brionzotos, E. (2012). Quality-improvement guidelines for hepatic transarterial chemoembolization. Cardiovasc. Intervent. Radiol. 35, 765–774. doi:10.1007/s00270-012-0423-z

Bolondi, L., Burroughs, A., Dufour, J. F., Galle, P. R., Mazzaferrro, V., Pisacchia, F., et al. (2012). Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisionisation to facilitate treatment decisions. Semin. Liver Dis. 32, 348–359. doi:10.1055/s-0032-1329906

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, L. R., Torre, L. A., and Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J. Clin. 68, 394–424. doi:10.3322/caac.21492

Brown, K. T., Do, R. K., Gonen, M., Covey, A. M., Getrajdman, G. I., Sofocleous, C. A., Aronsen, K. F., Hellekant, C., Holmberg, J., Rothman, U., and Teder, H. (1979). Prospective randomized study of doxorubicin-eluting-bead transcatheter arterial chemoembolization for treating Barcelona clinic liver cancer stage 0/A hepatocellular carcinoma. Cardiovasc. Intervent. Radiol. 43 (1), 55–64. doi:10.1007/s00270-019-02349-9

Kirstein, M. M., Schweitzer, N., Ay, N., Boeck, C., Lappas, K., Hirnrichs, J. B., et al. (2017). Experience from a real-life cohort: outcome of 606 patients with hepatocellular carcinoma following transarterial chemoembolization. Scand. J. Gastroenterol. 52, 116–124. doi:10.1002/sjg.36552.2016.1233579

Lammer, J., Malagari, K., Malagari, K., Vogl, T., Pilleul, F., Denys, A., et al. (2010). Randomized prospective study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc. Intervent. Radiol. 33 (1), 41–52. doi:10.1007/s00270-009-9711-7

Lencioni, R., de Baere, T., Soulen, M. C., Billing, W. S., and Geschwind, J.-F. H. (2016). Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data and efficacy and safety data. Hepatology 64 (1), 106–116. doi:10.1002/hep.28453

Lencioni, R., and Llovet, J. (2010). Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin. Liver Dis. 30 (1), 052–060. doi:10.1055/s-0030-1247132

Li, X., Feng, G. S., Zheng, C. S., Zhuo, C. K., and Liu, X. (2004). Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J. Gastroenterol. 10 (19), 2878–2882. doi:10.3748/wjg.v10.i19.2878

Llovet, J., Bru, C., and Bruix, J. (1999). Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis. 19 (3), 329–338. doi:10.1055/s-2007-1007122

Llovet, J., and Bruix, J. (2003). Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37, 429–442. doi:10.1053/jhep.2003.50047

Llovet, J. M., Real, M. I., Montañà, X., Planas, R., Coll, S., Aponte, J., et al. (2002). Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 358, 1739–1743. doi:10.1016/s0140-6736(02)08649-x

Lo, C. M., Nigan, H., Tso, W. K., Liu, C. L., Lam, C. M., Poont, R. P., et al. (2002). Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35, 1164–1171. doi:10.1053/hep.2002.33156

Mazaforro, V., Llovet, J. M., Miceli, R., Bhoori, S., Schild, M., Mariani, L., et al. (2009). Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 10 (1), 35–43. doi:10.1016/s1470-2045(08)70284-5

Mazaforro, V., Bhoori, S., Sposito, C., Bongini, M., Langer, M., Miceli, R., et al. (2011). Milan criteria in liver transplantation for hepatocellular carcinoma: an

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Comitato Etico Regione Calabria Area Centro, Catanzaro, Italy. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

RM and DL conceived the study concepts and design. RM, FM, MA, and GC performed literature research and assisted in data collection. RM, IK, and MS were in charge of manuscript editing. MM and RM performed the statistical analysis using the provided database. All authors read and approved the final manuscript.
evidence-based analysis of 15 years of experience. Liver Transpl. 17, S44–S57. doi:10.1002/lt.22365

National Institute of Cancer (2010). Common Terminology criteria for adverse events (CTCAE) version 4.0. Available at: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.

Niessen, C., Unterpaintner, E., Goessmann, H., Schlitt, H. J., Mueller-Schilling, M., Wohlgemuth, W. A., et al. (2014). Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma. J. Vasc. Interv. Radiol. 25 (2), 240–247. doi:10.1016/j.jvir.2013.10.007

Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., et al. (1982). Toxicity and response criteria of the eastern cooperative oncology group. Am. J. Clin. Oncol. 5, 649–656. doi:10.1097/00000421-198212000-00014

Orlacchio, A., Chegai, F., Merolla, S., Francioso, S., Del Giudice, C., Angelico, M., et al. (2015). Downstaging disease in patients with hepatocellular carcinoma outside up-to-seven criteria: strategies using degradable starch microspheres transcatheter arterial chemo-embolization. World J. Hepatol. 7 (12), 1694–1700. doi:10.4254/wjh.v7.i12.1694

Parikh, N. D., Waljee, A. K., and Singal, A. G. (2015). Downstaging hepatocellular carcinoma: a systematic review and pooled analysis. Liver Transpl. 21, 1142–1152. doi:10.1002/lt.24169

Sieghart, W., Hücke, F., Pinter, M., Graziaidei, I., Vogel, W., Muller, C., et al. (2013). The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology 57 (6), 2261–2273. doi:10.1002/hep.26256

Varela, M., Real, M. I., Burrell, M., Forner, A., Sala, M., Brunet, M., et al. (2007). Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J. Hepatol. 46 (3), 474–481. doi:10.1016/j.jhep.2006.10.020

Vogel, A., Cervantes, A., Chau, I., Daniele, B., Llovet, J. M., Meyer, T., et al. (2018). Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 29 (4), iv238–iv255. doi:10.1093/annonc/mdy308

Yao, F. Y., Mehta, N., Flemming, J., Dodge, J., Hameed, B., Fix, O., et al. (2015). Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology 61, 1968–1977. doi:10.1002/hep.27752

Zhang, Y., Zhang, M., Chen, M., Mei, J., Xu, L., Guo, R., et al. (2018). Association of sustained response duration with survival after conventional transarterial chemoembolization in patients with hepatocellular carcinoma. JAMA Netw. Open 1 (6), e183213. doi:10.1001/jamanetworkopen.2018.3213

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Minici, Ammendola, Manti, Siciliano, Minici, Komaei, Carro and Laganà. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.